Summary
The product Blue Top Peptide Vial, manufactured by Mintanabolics, underwent independent testing to verify its composition and purity. The sample was submitted by Mintanabolics and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of Tirzepatide at 10.38 mg, with a high purity level of 99.563%.
The testing process began on 15 August 2024, with the sample received on 26 August 2024, and analysis completed on 27 August 2024. While the results confirm high purity and expected composition, independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Mintanabolics
- Product Name: Blue Top Peptide Vial
- Active Ingredient: Tirzepatide
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Viral Powder
Sample Acquisition and Testing
- Task Number: #47997
- Testing Ordered: 15 August 2024
- Sample Received: 26 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Mintanabolics (Manufacturer)
- Analysis Paid For By: Mintanabolics (Manufacturer)
Testing Results
- Tirzepatide Concentration: 10.38 mg
- Purity: 99.563%
Verification Details
Verification URL: https://janoshik.com/tests/47997_S9YSW54HE64Q
Evaluation of Manufacturer-Submitted Testing
This analysis provides transparency regarding the product’s composition but also raises the need for external validation. Since Mintanabolics submitted and funded the test, independent verification through third-party testing across multiple batches would be beneficial. While Janoshik Analytical is recognized for its rigorous protocols, further scrutiny is encouraged to ensure product consistency.
Conclusion
The analysis confirms that Blue Top Peptide Vial contains Tirzepatide at 10.38 mg, with an exceptionally high purity of 99.563%. While this batch exhibits strong quality control, continued testing is essential to verify consistency across multiple production runs. This report aims to support educational and harm reduction efforts, assisting consumers in making informed decisions regarding peptide-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it still provides useful data when critically assessed alongside third-party results. Readers are encouraged to use this information responsibly.
